Repligen to Report Third Quarter 2019 Financial Results
October 23, 2019 10:29 ET
|
Repligen Corporation
WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31,...
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
August 01, 2019 07:30 ET
|
Repligen Corporation
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growthRaises revenue guidance to $264-$268 million for full year 2019, representing 29%-31%...
Repligen to Report Second Quarter 2019 Financial Results
July 23, 2019 16:01 ET
|
Repligen Corporation
WALTHAM, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2019 financial results on Thursday, August 1,...
Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options
July 19, 2019 19:42 ET
|
Repligen Corporation
WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of...
Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
July 17, 2019 00:14 ET
|
Repligen Corporation
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its...
Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes
July 15, 2019 16:02 ET
|
Repligen Corporation
WALTHAM, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten public offerings of $100,000,000 in...
Repligen to Present at Jefferies 2019 Healthcare Conference
June 04, 2019 10:03 ET
|
Repligen Corporation
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres,...
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
May 09, 2019 07:30 ET
|
Repligen Corporation
Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growthRaises revenue guidance to $235-$241 million for full year 2019, representing 22%-25%...
Repligen to Report First Quarter 2019 Financial Results
May 02, 2019 14:20 ET
|
Repligen Corporation
WALTHAM, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019 financial results on Thursday, May 9, 2019....
Repligen Corporation Prices Public Offering of Shares of Common Stock
April 30, 2019 19:36 ET
|
Repligen Corporation
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a...